111.04

2.70% 2.92

Oruka Therapeutics Inc (ORKA)

Overview News Price History Discussions Forecast

Oruka Therapeutics Inc stock is traded at $111.04, with a volume of 1.05M. It is up +2.70% in the last 24 hours and up +26.95% over the past month. Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Previous Close:

$108.12

Open:

$106.02

24h Volume:

1.05M

Relative Volume:

0.82

Market Cap:

$7.35B

Revenue:

Net Income/Loss:

$-116.25M

P/E Ratio:

-46.44

EPS:

-2.3912

Net Cash Flow:

$-91.19M

1W Performance:

+12.37%

1M Performance:

+26.95%

6M Performance:

+244.74%

1Y Performance:

+640.27%

1-Day Range:

$105.10

$111.37

1-Week Range:

$95.50

$111.37

52-Week Range:

$14.08

$111.37

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name

Oruka Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

650-606-7910

Address

855 OAK GROVE AVE., MENLO PARK

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

ORKA's Discussions on Twitter

Compare ORKA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORKA Oruka Therapeutics Inc	111.04	7.11B	0	-116.25M	-91.19M	-2.3912
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Piper Sandler	Overweight
Nov-13-25	Initiated	Jefferies	Buy
Oct-27-25	Initiated	Guggenheim	Buy
Oct-13-25	Initiated	Barclays	Overweight
May-22-25	Initiated	BTIG Research	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Oct-11-24	Initiated	Stifel	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	Leerink Partners	Outperform
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy
Oct-09-13	Initiated	Dawson James	Buy

View All

Oruka Therapeutics Inc Stock (ORKA) Latest News

Aug 14, 2026

Oruka Therapeutics GC Paul Quinlan sells $5.64m stock By Investing.com - Investing.com Nigeria

Aug 14, 2026

Oruka Therapeutics GC Paul Quinlan sells $5.64m stock - Investing.com

Aug 14, 2026

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock - MarketBeat

Aug 14, 2026

Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m By Investing.com - Investing.com South Africa

Aug 14, 2026

Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m - Investing.com UK

Aug 14, 2026

Oruka Therapeutics Insider Sold Shares Worth $5,641,409, According to a Recent SEC Filing - marketscreener.com

Aug 14, 2026

Oruka Therapeutics stock hits 52-week high at 109.56 USD By Investing.com - Investing.com Nigeria

Aug 14, 2026

Oruka Therapeutics stock hits 52-week high at 109.56 USD - Investing.com

Aug 14, 2026

Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA - MarketBeat

Aug 14, 2026

Aug 13, 2026

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits

Aug 13, 2026

Sei Investments Co. Raises Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat

Aug 13, 2026

Aug 12, 2026

Oruka Therapeutics (ORKA) On Its Earnings Miss And Whether The Valuation Still Holds - Sahm

Aug 12, 2026

A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180 - Moomoo

Aug 12, 2026

Dimensional Fund Advisors LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat

Aug 12, 2026

Aug 11, 2026

Oruka Therapeutics (ORKA) Is Up 10.9% After Wider-Than-Expected Q2 Loss From R&D InvestmentHas The Bull Case Changed? - simplywall.st

Aug 11, 2026

Oruka Therapeutics' (ORKA) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat

Aug 11, 2026

Oruka Therapeutics' (ORKA) Outperform Rating Reiterated at Wedbush - MarketBeat

Aug 11, 2026

Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat

Aug 11, 2026

Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighStill a Buy? - MarketBeat

Aug 11, 2026

Aug 10, 2026

ORUKA THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $179 FROM $162 - Bitget

Aug 10, 2026

Oruka Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 10, 2026

Oruka Therapeutics Q2 Loss Widens - marketscreener.com

Aug 10, 2026

Oruka Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Oruka Therapeutics Q2 EPS of $(0.55) misses estimates - scanx.trade

Aug 10, 2026

Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat

Aug 10, 2026

Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss - marketscreener.com

Aug 10, 2026

Oruka Therapeutics Q2 net loss widens on higher R&D costs - TradingView

Aug 10, 2026

Oruka Therapeutics reports Q2 2026 results: $1.1B cash; net loss $41.2M in quarter - TradingView

Aug 10, 2026

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 10, 2026